15/08/2026
Two particles can carry the exact same amount of cholesterol and do very different damage to an artery. The blood test almost everyone gets measures the cholesterol. It does not measure the thing that actually varies: what kind of particle is carrying it.
Every particle that can build plaque, whether it is LDL, a triglyceride-rich remnant, or lipoprotein(a), carries exactly one molecule of a protein called apolipoprotein B, or apoB. One particle, one apoB.
That is what makes apoB useful: it is a direct headcount of how many plaque-causing particles are in your blood. A standard cholesterol panel does something different. It weighs the total cholesterol those particles are hauling, not how many particles there are. Most of the time the two line up. When they do not, decades of data say the same thing: risk follows the particle count, not the cholesterol number. This is the finding that reframes the whole panel, because it means a normal LDL cholesterol can sit on top of a high particle count, and the standard test will read reassuring while the risk is real.
The next question is whether every particle in that count is equally dangerous, and it is not.
LDL is the baseline. It enters the artery wall, can lodge there, and drives plaque, and because it is the most common apoB particle, it makes up the bulk of the count for most people. It is the reference against which the others are judged.
Remnants are worse, particle for particle. These are the leftovers of triglyceride-rich lipoproteins, larger particles that have dropped their fat and are on their way to being cleared. They are retained in the artery wall more readily than LDL, they carry more cholesterol per particle, and they provoke inflammation and foam-cell formation once they are stuck. They contribute to cardiovascular risk beyond what LDL cholesterol captures, which is why someone with normal LDL cholesterol but high triglycerides, common with insulin resistance and metabolic syndrome, can be carrying a risk their panel understates.
Lipoprotein(a), or Lp(a), is the one that does far more damage, and it is different in kind, not just degree. It is an LDL particle with an extra protein tail, apo(a), wrapped around it, and that tail resembles a clotting protein, adding a pro-thrombotic dimension the other particles do not have. The evidence that it causes disease is not just association. Genetic studies, which track people who inherited high Lp(a) from birth, show it is a direct causal driver, and high levels predict roughly a two- to threefold increase in the risk of heart attack, peripheral artery disease, and calcific aortic valve stenosis. And here is the part that matters for anyone reading this: your Lp(a) level is set almost entirely by your genes, diet and exercise barely move it, and roughly one in five people carry a high level. It is one of the strongest inherited cardiovascular risk factors there is, and it is measured with a single blood test that most people have never had ordered.
Particle count and particle type sharpen risk assessment, but they do not replace the rest of the picture, blood pressure, smoking, and the standard lipids still matter, and no single marker decides an individual's fate. And identifying a high-risk particle is not the same as having a proven way to lower the risk it carries. LDL and remnants respond to established therapies, but targeted Lp(a)-lowering drugs are still in trials, and until those trials report, a high Lp(a) is information that sharpens prevention rather than a number with its own treatment. The practical reframe stands anyway. The standard panel counts cholesterol and treats every apoB particle as interchangeable. They are not. Two of the three particles that matter most, remnants and Lp(a), are the ones a routine cholesterol number is least equipped to see.
Glavinovic et al., J Am Heart Assoc 2022
Cantey & Wilkins, Curr Opin Endocrinol Diabetes Obes 2018
Pinto et al., Clin Investig Arterioscler 2023
Kamstrup, Clin Chem 2021
13/08/2026
13/08/2026
13/08/2026
13/08/2026
12/08/2026